Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004982
Status:
COMPLETED
Last Update Posted:
2010-01-14
First Post:
2000-03-13
Brief Title:
Combination Iron Chelation Therapy
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with beta-thalassemia Cooleys Anemia continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy Compliance with the use of the only FDA-approved drug for removing excess iron from patients Desferal continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy If both drugs can be given orally there may be a better chance of finding a suitable alternative to Desferal Several combinations of experimental iron chelating drugs are being used in this trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01DK055463-01 | NIH | None | httpsreporternihgovquickSearch1R01DK055463-01 |